Institutional shares held 9.65 Million
1.16M calls
1.98M puts
Total value of holdings $8.39M
$1.01M calls
$1.72M puts
Market Cap $51.7M
59,426,000 Shares Out.
Institutional ownership 16.24%
# of Institutions 91


Latest Institutional Activity in GALT

Top Purchases

Q3 2024
Soltis Investment Advisors LLC Shares Held: 141K ($122K)
Q3 2024
Northern Trust Corp Shares Held: 234K ($204K)
Q3 2024
Sanctuary Advisors, LLC Shares Held: 79.1K ($68.8K)
Q3 2024
Advisor Group Holdings, Inc. Shares Held: 1.18M ($1.03M)
Q3 2024
Kovitz Investment Group Partners, LLC Shares Held: 42.5K ($37K)

Top Sells

Q3 2024
Susquehanna International Group, LLP Shares Held: 81.5K ($70.9K)
Q3 2024
Squarepoint Ops LLC Shares Held: 27.4K ($23.9K)
Q3 2024
Man Group PLC Shares Held: 12.7K ($11K)
Q3 2024
Geneos Wealth Management Inc. Shares Held: 353K ($307K)
Q3 2024
New York State Common Retirement Fund Shares Held: 12.6K ($11K)

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.


Insider Transactions at GALT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
60.1K Shares
From 7 Insiders
Grant, award, or other acquisition 34.9K shares
Open market or private purchase 23.2K shares
Acquisition or disposition by will or laws 2.06K shares
Sell / Disposition
178K Shares
From 2 Insiders
Grant, award, or other acquisition 153K shares
Open market or private sale 25K shares

Track Institutional and Insider Activities on GALT

Follow GALECTIN THERAPEUTICS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GALT shares.

Notify only if

Insider Trading

Get notified when an Galectin Therapeutics Inc insider buys or sells GALT shares.

Notify only if

News

Receive news related to GALECTIN THERAPEUTICS INC

Track Activities on GALT